Variation in serum adrenal hormones in female 21-hydroxylase deficient patients
- PMID: 35904224
- PMCID: PMC9254284
- DOI: 10.1530/EC-22-0143
Variation in serum adrenal hormones in female 21-hydroxylase deficient patients
Abstract
Background: There is no consensus regarding markers of optimal treatment or timing between glucocorticoid intake and assessment of hormone levels in the follow-up of female 21-hydroxylase deficient patients.
Objective: To examine visit-to-visit repeatability in levels of adrenal hormones in adult female patients, to identify predictors of repeatability in hormone levels and to examine concordance between levels of different adrenal hormones.
Method: All patients with confirmed 21-hydroxylase deficiency treated with glucocorticoids, were included. The two most recent blood samples collected on a stable dose of glucocorticoid replacement were compared. Complete concordance was defined as all measured adrenal hormones either within, below or above normal range evaluated in a single-day measurement.
Results: Sixty-two patients, median age of 35 (range 18-74) years were included. All hormone levels showed moderate to excellent repeatability with an intraclass correlation coefficient between 0.80 and 0.99. Repeatability of hormone levels was not affected by the use of long-acting glucocorticoids or time of day for blood sample collection. The median difference in time between the two sample collections was 1.5 (range 0-7.5) h. Complete concordance between 17-hydroxyprogesterone, androstenedione, and testosterone was found in 21% of cases.
Conclusion: During everyday, clinical practice hormone levels in adult female patients with 21-hydroxylase deficiency showed a moderate to excellent repeatability, despite considerable variation in time of day for blood sample collection. We found no major predictors of hormone level variation. Future studies are needed to address the relationship between the timing of glucocorticoid intake vs adrenal hormone levels and clinical outcome in both adults and children.
Keywords: 17-hydroxyprogesterone; 21-hydroxylase deficiency; CAH; DHEAs; androstenedione; testosterone.
Figures




Similar articles
-
The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism.Clin Endocrinol (Oxf). 2003 May;58(5):601-11. doi: 10.1046/j.1365-2265.2003.01759.x. Clin Endocrinol (Oxf). 2003. PMID: 12699442
-
Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.J Rheumatol. 2002 Apr;29(4):748-56. J Rheumatol. 2002. PMID: 11950017 Clinical Trial.
-
Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?J Clin Endocrinol Metab. 2001 Oct;86(10):4679-85. doi: 10.1210/jcem.86.10.7972. J Clin Endocrinol Metab. 2001. PMID: 11600525
-
Monitoring of therapy in congenital adrenal hyperplasia.Clin Chem. 2010 Aug;56(8):1245-51. doi: 10.1373/clinchem.2010.146035. Epub 2010 Jun 17. Clin Chem. 2010. PMID: 20558634 Review.
-
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults.Endokrynol Pol. 2010 Jan-Feb;61(1):142-55. Endokrynol Pol. 2010. PMID: 20205117 Review.
References
-
- Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SE, et al.Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 20181034043–4088. (10.1210/jc.2018-01865) - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources